Global Epilepsy Market: Industry Analysis & Outlook (2017-2021) – Koncept Analytics

Press Release (ePRNews.com) - DELHI, India - Feb 21, 2017 - Epilepsy is a group of neurological diseases characterized by epileptic seizures. Epileptic seizures are episodes that can vary from brief and nearly undetectable to long periods of vigorous shaking. These episodes can result in physical injuries including occasionally broken bones. The medical definition of this disease is as a “condition characterized by recurrent (two or more) epileptic seizures, unprovoked by any immediate identified cause”. Epilepsy is divided into four main types; idiopathic generalized epilepsy, idiopathic partial epilepsy, symptomatic generalized epilepsy and symptomatic partial epilepsy. The cause of epilepsy can be genetic, a result of other disorders such as tumor or brain injury and due to certain seizure triggers.

The high incidence and prevalence of epilepsy in developing countries has partly been attributed to an increased frequency of central nervous system (CNS) infections. Of the CNS infections, bacterial meningitis is endemic in many countries and several epidemics have also been reported in these (parts of Africa, Latin America and Asia) regions. Unprovoked seizures and epilepsy (recurrent unprovoked seizures) can be long-term sequelae of bacterial meningitis.

The probability of developing an unprovoked seizure or epilepsy varies according to the etiologic agent responsible for meningitis and this probability appears to be higher for Streptococcus pneumoniae. The risk factors for late unprovoked seizures/epilepsy include early seizures during the acute phase of meningitis and persistent neurological deficits other than sensorineural hearing loss. The majority of unprovoked seizures occurs within 5 years of the meningitis episode and tends to be recurrent. The burden of epilepsy associated with bacterial meningitis depends upon the incidence of the latter. Thus the higher prevalence of these diseases will contribute to the patient count and will promote the market growth.

The report “Global Epilepsy Drugs Market: Industry Analysis & Outlook (2017-2021)” analyzes the development of this market, with focus on the Americas, EMEA and APAC regions. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Novartis AG., Pfizer Inc., GlaxoSmithKline Plc. and UCB are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global epilepsy drugs market along with the study of the regional markets.

List of Charts

Causes of Epilepsy
Treatment Options Available for Epilepsy
Antiepileptic Drugs Market Segmentation
Global Antiepileptic Drugs Market Forecast by Value (2016-2021)
Global Antiepileptic Drugs Market by Region (2016)
Global Antiepileptic Market by Drug Type (2016)
Global Branded Antiepileptic Drugs Market Forecast by Value (2016-2021)
Global Generic Antiepileptic Drugs Market Forecast by Value (2016-2021)
Global Branded Antiepileptic Market by Drug Class (2016)
Global Second Generation Antiepileptic Drugs Market Forecast by Value (2016-2021)
Global Third Gen Branded Antiepileptic Drugs Market Forecast by Value (2016-2021)
Global First Generation Antiepileptic Drugs Market Forecast by Value (2016-2021)
Americas Antiepileptic Drugs Market Forecast by Value (2016-2021)
The US Antiepileptic Drugs Market Forecast by Value (2016-2021)
The US Antiepileptic Drugs Prescription Forecast by Volume (2016-2021)
The US Child Epileptic Patients by Volume (2016-2021)
The US Child Pharmacoresistant Epilepsy Patient by Volume (2016-2021)
EMEA Antiepileptic Drugs Market Forecast by Value (2016-2021)
Europe Child Epileptic Patients by Volume (2016-2021)
Europe Child Pharmacoresistant Epilepsy Patients Forecast by Volume (2016-2021)
APAC Antiepileptic Drugs Market Forecast by Value (2016-2021)
Japan Antiepileptic Drugs Market Forecast by Value (2016-2021)
China Antiepileptic Drugs Market Forecast by Value (2016-2021)
India Antiepileptic Drugs Market Forecast by Value (2016-2021)
Global Healthcare Expenditure Per Capita (2012-2016)
Global GDP Per Capita (2012-2016)
Antiepileptic Drugs in Pipeline (2016)
Global Antiepileptic Drugs Market Share (2016)
Global Antiepileptic Drugs Market Share Forecast (2021)
The US Antiepileptic Drugs Market Share (2016)
The US Antiepileptic Drugs Market Share Forecast (2021)
Novartis AG Revenue by Segment (2015)
Novartis AG Net Sales and Net Income (2011-2015)
Novartis AG R&D Expenditure (2013-2015)
Pfizer Inc. Revenue by Segment (2015)
Pfizer Inc. Revenue and Net Income (2011-2015)
Pfizer Inc. R&D Expenditure (2013-2015)
GlaxoSmithKline Plc. Net Sales Share by Segments (2015)
GlaxoSmithKline Plc. Net Sales and Operating Profit (2012-2015)
UCB Revenue by Region (2015)
UCB Revenue and Profit (2011-2015)
UCB R&D Expenditure (2013-2015)

List of Tables

Different Types of Epilepsy
Antiepileptic Drugs in Pipeline (2016)
New Products of Pfizer with FDA Approval (2015/2016)
GlaxoSmithKline Plc. Core R&D Expenditure Allocation (2015)
GSK Product Development Pipeline in Pharmaceutical and Vaccine Segment (2015)

For more Information:

http://www.konceptanalytics.com/Researchreport/global-epi…

Koncept Analytics

Vikas Gupta

(Business Development Manager)

FFCS-36, Ansal Plaza

Vaishali, Ghaziabad

U.P – 201010

Tele: +91-120-4130959

Mobile: +91-9871694789

Mail ID – vikas@konceptanalytics.com

Source : Koncept Analytics

You may also like this  

CATEGORIES : Reports
DISCLAIMER : If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/services/business mentioned and hereby disclaims any content contained in this press release.

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login